• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Staphylococcus Aureus Infections - Pipeline Review, H2 2012 Product Image

Staphylococcus Aureus Infections - Pipeline Review, H2 2012

  • Published: November 2012
  • 311 pages
  • Global Markets Direct

Staphylococcus Aureus Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Staphylococcus Aureus Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Staphylococcus Aureus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections.
- A review of READ MORE >

2
List of Tables 7
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Staphylococcus Aureus Infections Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Staphylococcus Aureus Infections 13
Staphylococcus Aureus Infections Therapeutics under Development by Companies 15
Staphylococcus Aureus Infections Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 25
Comparative Analysis 25
Mid Clinical Stage Products 26
Comparative Analysis 26
Early Clinical Stage Products 27
Comparative Analysis 27
Discovery and Pre-Clinical Stage Products 28
Comparative Analysis 28
Staphylococcus Aureus Infections Therapeutics – Products under Development by Companies 29
Staphylococcus Aureus Infections Therapeutics – Products under Investigation by Universities/Institutes 36
Companies Involved in Staphylococcus Aureus Infections Therapeutics Development 37
AlphaRx, Inc. 37
AstraZeneca PLC 38
GlaxoSmithKline plc 39
Genentech, Inc. 40
Daiichi Sankyo Company, Ltd 41
Takeda Pharmaceutical Company Limited 42
Piramal Healthcare Limited 43
Rib-X Pharmaceuticals, Inc. 44
Aphios Corporation 45
Achillion Pharmaceuticals, Inc. 46
Actelion Ltd 47
BioMarin Pharmaceutical Inc. 48
Cubist Pharmaceuticals, Inc. 49
Forest Laboratories, Inc. 50
Pfizer Inc. 51
Wockhardt Limited 52
Paratek Pharmaceuticals, Inc. 53
Alchemia Limited 54
Helix BioMedix, Inc. 55
Immtech Pharmaceuticals, Inc. 56
Lorus Therapeutics Inc 57
Basilea Pharmaceutica Ltd. 58
Biota Holdings Limited 59
Oragenics, Inc. 60
Patrys Limited 61
CytoGenix, Inc. 62
SIGA Technologies, Inc. 63
Theravance, Inc. 64
CrystalGenomics, Inc. 65
Phynova Group Ltd 66
Syntopix Group Plc 67
PolyMedix, Inc. 68
e-Therapeutics plc 69
Bharat Biotech International Limited 70
Immupharma Plc 71
MerLion Pharmaceuticals Pte Ltd 72
Evolva SA 73
Novabiotics Ltd 74
GlycoVaxyn AG 75
ConjuGon, Inc. 76
PLANTON GmbH 77
Aquapharm Biodiscovery Limited 78
MicuRx Pharmaceuticals, Inc. 79
Mondobiotech Holding AG 80
Destiny Pharma Ltd. 81
NovaDigm Therapeutics, Inc. 82
Kenta Biotech Ltd. 83
aRigen Pharmaceuticals, Inc. 84
Nabriva Therapeutics AG 85
Concert Pharmaceuticals, Inc. 86
Inimex Pharmaceuticals, Inc. 87
NanoBio Corporation 88
Integrated BioTherapeutics, Inc. 89
Enanta Pharmaceuticals, Inc. 90
Canopus BioPharma Incorporated 91
Cempra Pharmaceuticals, Inc. 92
Ancora Pharmaceuticals Inc. 93
KYORIN Pharmaceutical Co., Ltd. 94
Trius Therapeutics, Inc. 95
Lytix Biopharma AS 96
Medisyn Technologies, Inc. 97
PALUMED S.A. 98
Phico Therapeutics Ltd. 99
AIMM Therapeutics B.V. 100
Savara, Inc. 101
Sorrento Therapeutics, Inc. 102
TAXIS Pharmaceuticals, Inc. 103
GangaGen Inc. 104
SelectX Pharmaceuticals, Inc. 105
PepTx, Inc. 106
Durata Therapeutics Inc. 107
Cantab Biopharmaceuticals Limited 108
PharmaIN Corporation 109
Excelimmune, Inc. 110
UNeMed 111
Staphylococcus Aureus Infections – Therapeutics Assessment 112
Assessment by Monotherapy Products 112
Assessment by Combination Products 113
Assessment by Route of Administration 114
Assessment by Molecule Type 116
Drug Profiles 119
dalbavancin - Drug Profile 119
AR-2474 - Drug Profile 121
HB-1345 - Drug Profile 122
LOR-220 - Drug Profile 123
vancomycin - Drug Profile 124
lysostaphin - Drug Profile 125
ceftaroline fosamil - Drug Profile 126
omadacycline tosylate - Drug Profile 128
PYN-6 - Drug Profile 130
LT-29 - Drug Profile 132
lotilibcin - Drug Profile 133
lotilibcin - Drug Profile 134
PMX-70004 - Drug Profile 135
CY-403 - Drug Profile 136
MX-2401 - Drug Profile 137
TD-1792 - Drug Profile 138
Antibiotic Program - Drug Profile 140
Sortase Inhibitor - Drug Profile 141
MU-1140 - Drug Profile 142
KBSA-302 - Drug Profile 143
BC-7013 - Drug Profile 144
delafloxacin - Drug Profile 145
RX-04 - Drug Profile 148
KBSA-301 - Drug Profile 149
oxazolidinone - Drug Profile 150
XF-73 - Drug Profile 151
XF-73 - Drug Profile 152
210-infectious disease abs - Drug Profile 153
CG-400549 - Drug Profile 154
WCK- 771 - Drug Profile 155
oritavancin disphosphate - Drug Profile 156
fusidic acid - Drug Profile 158
PM-181104 - Drug Profile 160
vancomycin - Drug Profile 161
PA-1245 - Drug Profile 162
IMX-942 - Drug Profile 163
ETX-1153b - Drug Profile 164
CDI Program - Drug Profile 165
NVB-333 - Drug Profile 166
torezolid - Drug Profile 167
Lipopeptide Program - Drug Profile 169
EDP-322 - Drug Profile 170
MRX-I - Drug Profile 171
Lytixar - Drug Profile 172
Cotrimoxazole - Drug Profile 174
Marinus - Drug Profile 175
SYN-0854 - Drug Profile 176
SYN-0096 - Drug Profile 177
Rifabutin + Trimethoprim - Sulfamethoxazole - Drug Profile 178
Recombinant Human Beta-Defensin-2 - Drug Profile 180
GSK-2392106-A - Drug Profile 181
JNJ-Q2 - Drug Profile 182
ABI-0043 - Drug Profile 185
ceftobiprole medocaril - Drug Profile 186
IPP-203101 - Drug Profile 189
ceftaroline fosamil + avibactam sodium - Drug Profile 190
Co-trimaxazole - Drug Profile 192
Trimethoprim + Sulfamethoxazole + Cephalexin - Drug Profile 193
Trimethoprim + Sulfamethoxazole + Clindamycin - Drug Profile 195
Bactroban + Hibiclens - Drug Profile 197
GSK-2392105-A - Drug Profile 198
GSK-2392103-A - Drug Profile 199
GSK-2392019-A - Drug Profile 200
levonadifloxacin - Drug Profile 201
WCK- 4086 - Drug Profile 202
MRX-II - Drug Profile 203
Staphylococcus Aureus Vaccine - Drug Profile 204
Drug For MRSA - Drug Profile 205
Systemic Antibiotic - Drug Profile 206
Topical Antibiotic Drug Program - Drug Profile 207
ACH-2881 - Drug Profile 208
Antibiotic Program - Drug Profile 209
secretin - Drug Profile 210
AMR-BAC-1 - Drug Profile 211
AMR-BAC-2 - Drug Profile 212
AMR-BAC-3 - Drug Profile 213
Drug For MRSA - Drug Profile 214
NDV-3 Vaccine - Drug Profile 215
SLP-0905 - Drug Profile 217
SLP-0906 - Drug Profile 219
SLP-1003 - Drug Profile 221
SLP-0904 - Drug Profile 223
SLP-1004 - Drug Profile 224
Anti-Bacterial Program - Drug Profile 226
PGC Anti-MRSA - Drug Profile 227
SEB-HuMab - Drug Profile 228
EP-67 - Drug Profile 229
SASPject PT1.2 - Drug Profile 230
Anti-MRSA Program - Drug Profile 232
PF-06290510 - Drug Profile 233
Staphguard - Drug Profile 235
Anti-Bacterial Program - Drug Profile 236
Bactericidal Venom-Based Polypeptides - Drug Profile 237
CF-301 - Drug Profile 238
GSK-2392102-A - Drug Profile 239
vancomycin - Drug Profile 240
Second Generation Oxas - Drug Profile 241
vancomycin hydrochloride - Drug Profile 242
EV-035 - Drug Profile 244
KRP-AM1977X - Drug Profile 245
KRP-AM1977Y - Drug Profile 246
Quadrivan - 246
Drug Profile 247
IMV-0123 - Drug Profile 248
Staphylococcus Aureus Vaccine - Drug Profile 249
PTX-005 - Drug Profile 250
STI-001 Program - Drug Profile 251
AQP-182 - Drug Profile 252
Snare Antibacterial For MRSA - Drug Profile 253
Nicotinamide - Drug Profile 254
Drug For Gram Positive Bacterial Wound Infections - Drug Profile 255
CB-027 - Drug Profile 256
NB-401 - Drug Profile 257
daptomycin - Drug Profile 258
Compound G1 - Drug Profile 259
MU1140-S - Drug Profile 260
Vaccine for Staphylococcus - Drug Profile 262
Human Monoclonal Antibodies Program For MRSA - Drug Profile 263
Microbisporicin - Drug Profile 264
SXP-2554 - Drug Profile 265
P-128 - Drug Profile 266
DNA Ligase Inhibitors - Drug Profile 267
Azachryseniums Series - Drug Profile 268
MGB-BP-3 IV - Drug Profile 269
Staphylococcus Aureus Infections Therapeutics – Drug Profile Updates 270
Staphylococcus Aureus Infections Therapeutics – Discontinued Products 292
Staphylococcus Aureus Infections Therapeutics - Dormant Products 293
Staphylococcus Aureus Infections – Product Development Milestones 295
Featured News & Press Releases 295
Appendix 302
Methodology 302
Coverage 302
Secondary Research 302
Primary Research 302
Expert Panel Validation 302
Contact Us 303
Disclaimer 303

List of Tables
Number of Products Under Development for Staphylococcus Aureus Infections, H2 2012 21
Products under Development for Staphylococcus Aureus Infections – Comparative Analysis, H2 2012 22
Number of Products under Development by Companies, H2 2012 24
Number of Products under Development by Companies, H2 2012 (Contd..1) 25
Number of Products under Development by Companies, H2 2012 (Contd..2) 26
Number of Products under Development by Companies, H2 2012 (Contd..3) 27
Number of Products under Development by Companies, H2 2012 (Contd..4) 28
Number of Products under Development by Companies, H2 2012 (Contd..5) 29
Number of Products under Development by Companies, H2 2012 (Contd..6) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 32
Comparative Analysis by Late Stage Development, H2 2012 33
Comparative Analysis by Mid Clinical Stage Development, H2 2012 34
Comparative Analysis by Early Clinical Stage Development, H2 2012 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 36
Products under Development by Companies, H2 2012 37
Products under Development by Companies, H2 2012 (Contd..1) 38
Products under Development by Companies, H2 2012 (Contd..2) 39
Products under Development by Companies, H2 2012 (Contd..3) 40
Products under Development by Companies, H2 2012 (Contd..4) 41
Products under Development by Companies, H2 2012 (Contd..5) 42
Products under Development by Companies, H2 2012 (Contd..6) 43
Products under Investigation by Universities/Institutes, H2 2012 44
AlphaRx, Inc., H2 2012 45
AstraZeneca PLC, H2 2012 46
GlaxoSmithKline plc, H2 2012 47
Genentech, Inc., H2 2012 48
Daiichi Sankyo Company, Ltd, H2 2012 49
Takeda Pharmaceutical Company Limited, H2 2012 50
Piramal Healthcare Limited, H2 2012 51
Rib-X Pharmaceuticals, Inc., H2 2012 52
Aphios Corporation, H2 2012 53
Achillion Pharmaceuticals, Inc., H2 2012 54
Actelion Ltd, H2 2012 55
BioMarin Pharmaceutical Inc., H2 2012 56
Cubist Pharmaceuticals, Inc., H2 2012 57
Forest Laboratories, Inc., H2 2012 58
Pfizer Inc., H2 2012 59
Wockhardt Limited, H2 2012 60
Paratek Pharmaceuticals, Inc., H2 2012 61
Alchemia Limited, H2 2012 62
Helix BioMedix, Inc., H2 2012 63
Immtech Pharmaceuticals, Inc., H2 2012 64
Lorus Therapeutics Inc, H2 2012 65
Basilea Pharmaceutica Ltd., H2 2012 66
Biota Holdings Limited, H2 2012 67
Oragenics, Inc., H2 2012 68
Patrys Limited, H2 2012 69
CytoGenix, Inc., H2 2012 70
SIGA Technologies, Inc., H2 2012 71
Theravance, Inc., H2 2012 72
CrystalGenomics, Inc., H2 2012 73
Phynova Group Ltd, H2 2012 74
Syntopix Group Plc, H2 2012 75
PolyMedix, Inc., H2 2012 76
e-Therapeutics plc, H2 2012 77
Bharat Biotech International Limited, H2 2012 78
Immupharma Plc, H2 2012 79
MerLion Pharmaceuticals Pte Ltd, H2 2012 80
Evolva SA, H2 2012 81
Novabiotics Ltd, H2 2012 82
GlycoVaxyn AG, H2 2012 83
ConjuGon, Inc., H2 2012 84
PLANTON GmbH, H2 2012 85
Aquapharm Biodiscovery Limited, H2 2012 86
MicuRx Pharmaceuticals, Inc., H2 2012 87
Mondobiotech Holding AG, H2 2012 88
Destiny Pharma Ltd., H2 2012 89
NovaDigm Therapeutics, Inc., H2 2012 90
Kenta Biotech Ltd., H2 2012 91
aRigen Pharmaceuticals, Inc., H2 2012 92
Nabriva Therapeutics AG, H2 2012 93
Concert Pharmaceuticals, Inc., H2 2012 94
Inimex Pharmaceuticals, Inc., H2 2012 95
NanoBio Corporation, H2 2012 96
Integrated BioTherapeutics, Inc., H2 2012 97
Enanta Pharmaceuticals, Inc., H2 2012 98
Canopus BioPharma Incorporated, H2 2012 99
Cempra Pharmaceuticals, Inc., H2 2012 100
Ancora Pharmaceuticals Inc., H2 2012 101
KYORIN Pharmaceutical Co., Ltd., H2 2012 102
Trius Therapeutics, Inc., H2 2012 103
Lytix Biopharma AS, H2 2012 104
Medisyn Technologies, Inc., H2 2012 105
PALUMED S.A., H2 2012 106
Phico Therapeutics Ltd., H2 2012 107
AIMM Therapeutics B.V., H2 2012 108
Savara, Inc., H2 2012 109
Sorrento Therapeutics, Inc., H2 2012 110
TAXIS Pharmaceuticals, Inc., H2 2012 111
GangaGen Inc., H2 2012 112
SelectX Pharmaceuticals, Inc., H2 2012 113
PepTx, Inc., H2 2012 114
Durata Therapeutics Inc., H2 2012 115
Cantab Biopharmaceuticals Limited, H2 2012 116
PharmaIN Corporation, H2 2012 117
Excelimmune, Inc., H2 2012 118
UNeMed, H2 2012 119
Assessment by Monotherapy Products, H2 2012 120
Assessment by Combination Products, H2 2012 121
Assessment by Stage and Route of Administration, H2 2012 123
Assessment by Stage and Molecule Type, H2 2012 126
Staphylococcus Aureus Infections Therapeutics – Drug Profile Updates 278
Staphylococcus Aureus Infections Therapeutics – Discontinued Products 300
Staphylococcus Aureus Infections Therapeutics – Dormant Products 301
Staphylococcus Aureus Infections Therapeutics – Dormant Products (Contd..1) 302

List of Figures
Number of Products under Development for Staphylococcus Aureus Infections, H2 2012 21
Products under Development for Staphylococcus Aureus Infections – Comparative Analysis, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 31
Late Stage Products, H2 2012 33
Mid Clinical Stage Products, H2 2012 34
Early Clinical Stage Products, H2 2012 35
Discovery and Pre-Clinical Stage Products, H2 2012 36
Assessment by Monotherapy Products, H2 2012 120
Assessment by Combination Products, H2 2012 121
Assessment by Route of Administration, H2 2012 122
Assessment by Stage and Route of Administration, H2 2012 123
Assessment by Molecule Type, H2 2012 124
Assessment by Stage and Molecule Type, H2 2012 125

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos